Figure 1.

DCA and sirtinol synergistically inhibit the growth of A549 and H1299 cells. (A) A549 cells were incubated with sirtinol and a small screen of compounds for 72h. DCA was identified as a possible agent that could synergistically inhibit A549 cell survival. (B) A549, H1299 and HFL-1 cells were treated with the indicated concentrations of DCA and sirtinol or AGK2 for 72h and cell survival was detected by CCK8 assay. Each bar represents the means ± SD of three separate experiments. (C) A549, H1299, H522 and PC9 cells were incubated with DCA and Sirtinol either alone or in combination (1:1000). CCK8 assay was performed to determine the cytotoxic effect. The dose-effect curve and the combination index (CI) values were analyzed by CompuSyn software. Synergy was defined as CI values lower than 1.0. (D) Each mouse was injected subcutaneously with A549 cells under the shoulder. When the tumors were palpable, mice were randomly assigned to treatment with vehicle, DCA (75 mg/kg intraperitoneal[i.p.] injection, three times/week;), Sirtinol (4 mg/kg i.p, three times/week) or the drug combination. The tumors were removed and weighed on the twenty-second day. The original tumors are shown. The values presented are the means ± SD for each group. *P < 0.05 and **P < 0.01 vs. corresponding group.